AC Immune (ACIU) Total Current Liabilities (2015 - 2026)
AC Immune (ACIU) posted quarterly Total Current Liabilities of $117.8 billion for Q1 2026, up 106617.05% year-over-year from N/an in Q1 2025, and down 0.57% quarter-over-quarter from $118.5 billion in Q4 2025.
AC Immune (ACIU) Total Current Liabilities (2015 - 2026) Analysis & Trends
AC Immune (ACIU) has reported Total Current Liabilities for 12 consecutive years, with $117.8 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 106617.05% year-over-year to $117.8 billion; the TTM figure through Mar 2026 stood at $117.8 billion (up 106617.05% YoY), while the FY2025 annual figure was $114.2 billion, up 99120.86% from the prior year.
- Total Current Liabilities fell to $117.8 billion in Q1 2026 per ACIU's latest filing, from $118.5 billion in the prior quarter.
- Across five years, Total Current Liabilities topped out at $118.5 billion in Q4 2025 and bottomed at $11.6 million in Q1 2023.
- Historically, Total Current Liabilities has averaged $16.3 billion across 5 years, with a median of $115.1 million in 2024.
- Annual changes were most pronounced in 2022 — Total Current Liabilities sank 99.95% — and 2023, when it soared 128323.97%.
- AC Immune's Total Current Liabilities stood at $11.9 million in 2022, then surged by 128323.97% to $15.3 billion in 2023, then plunged by 99.25% to $115.1 million in 2024, then surged by 102826.14% to $118.5 billion in 2025, then decreased by 0.57% to $117.8 billion in 2026.
- Business Quant data shows ACIU's Total Current Liabilities at $117.8 billion in Q1 2026, $118.5 billion in Q4 2025, and $122.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | AC Immune | 253.89 Mn | 253.89 Mn | - | 126.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 126.83 Mn |
| Mar 31, 2026 | 117.80 Bn |
| Dec 31, 2025 | 118.48 Bn |
| Sep 30, 2025 | 122.87 Mn |
| Jun 30, 2025 | 119.54 Mn |
| Mar 31, 2025 | 110.39 Mn |
| Dec 31, 2024 | 115.11 Mn |
| Sep 30, 2024 | 116.56 Mn |
| Jun 30, 2024 | 111.17 Mn |
| Mar 31, 2024 | 16.18 Mn |
| Dec 31, 2023 | 15.30 Bn |
| Sep 30, 2023 | 13.26 Mn |
| Jun 30, 2023 | 12.40 Mn |
| Mar 31, 2023 | 11.63 Mn |
| Dec 31, 2022 | 11.92 Mn |
| Sep 30, 2022 | 14.08 Mn |
| Jun 30, 2022 | 12.38 Bn |
| Mar 31, 2022 | 12.90 Bn |
| Dec 31, 2021 | 21.72 Bn |
| Sep 30, 2021 | 15.49 Bn |